Nxera Pharma Shares Video Interviews with Major Shareholders on Its Official YouTube Channel
- Perspectives from Nxera’s major shareholders provide deeper insights into their investment views and confidence in the Company’s strategy
Tokyo, Japan and Cambridge and London, UK, 17 November 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces the release of two video interviews with its major shareholders, available on the Company’s official YouTube channel.
Nxera invited its major shareholders to share their perspectives on the Company’s strategy, operations and investment appeal, offering valuable insights for all stakeholders, including shareholders and investors, to better understand Nxera’s business.
In the first interview, conducted in July 2025, Nxera welcomed Mr. Yoshiharu Asai, a venture capitalist from JIC Venture Growth Investments Co., Ltd. (“JIC VGI”), part of the Japan Investment Corporation (“JIC”) Group. In the second interview, Nxera spoke with Mr. Daisuke Gomi, an individual shareholder.
Nxera continues to value open and proactive engagement with its stakeholders, including shareholders and investors, as part of its commitment to sustainable growth and long-term value creation. These initiatives reflect Nxera’s focus on fostering a deeper understanding of the Company’s corporate strategy and business initiatives.
Interview with Mr. Yoshiharu Asai, JIC VGI | 3 July 2025
Session topics:
- Background of the Investment in Nxera
- Valuation Approach
- Notable Pipeline in Nxera’s Platform Business
- Focus Areas in Nxera’s Commercial Business
- Impressions of the Management Team
Watch the full interview here:
Interview with Mr. Daisuke Gomi | 17 November 2025
Session topics:
- Focus Areas When Making Investment Decisions
- Reasons for Investing in Nxera and Other Bio-ventures
- Expectations of Nxera
- Evaluation of Nxera (Business, Management, etc.)
- Future Expectations
Watch the full interview here:
–END–
About Nxera Pharma
Nxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally.
We have built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high value, large and growing market and those in the broader APAC region.
Behind that, and powered by our unique NxWave™ discovery platform, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline of potentially first- and best-in-class candidates is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across obesity and metabolic disorders, neurology/neuropsychiatry and immunology and inflammation.
Nxera employs approximately 400 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565).
For more information, please visit
LinkedIn: | X: | YouTube:
Enquiries:
Media and Investor Relations
Shinya Tsuzuki, VP, Head of Investor Relations
Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures
Maya Bennison, Communications Manager
+81 (0)3 5962 5718 | +44 (0)1223 949390
MEDiSTRAVA (for International Media)
Mark Swallow, Frazer Hall, Erica Hollingsworth
+44 (0)203 928 6900 |
Forward-looking statements
This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group’s actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
